China greenlights new mRNA vaccine targeting tumors
China's pharmaceutical authority has greenlit new mRNA vaccine targeting Epstein-Barr virus (EBV) positive tumors for clinical trials. The vaccine has already shown success in preliminary trials targeting cancer related to EBV, including nasopharyngeal carcinoma and lymphoma.
- Health
- Anadolu Agency
- Published Date: 09:33 | 16 August 2024
- Modified Date: 09:35 | 16 August 2024
China's pharmaceutical regulatory authority has approved a new mRNA vaccine designed to target Epstein-Barr virus (EBV) positive tumors for Phase I clinical trials.
Developed by WestGene Biopharma, based in Chengdu, Sichuan Province, the vaccine had earlier received approval from the US Food and Drug Administration in May, according to Chinese state-run Xinhua News.
The vaccine has also successfully completed early trials for nasopharyngeal carcinoma and lymphoma, which are among the cancers linked to EBV, a Group-I carcinogen associated with over 10 types of cancer, including gastric cancer.
WestGene Biopharma plans to conduct further clinical trials to explore the vaccine's potential in advancing tumor immunotherapy.